| Revision as of 12:22, 28 April 2009 editVanished 45kd09la13 (talk | contribs)26,505 editsm →References← Previous edit | Revision as of 12:22, 28 April 2009 edit undoVanished 45kd09la13 (talk | contribs)26,505 editsm →ReferencesNext edit → | ||
| Line 10: | Line 10: | ||
| According to ] the tetracyclic antidepressants have the following effects: | According to ] the tetracyclic antidepressants have the following effects: | ||
| ⚫ | ==References== | ||
| ⚫ | {{reflist}} | ||
| {| class="wikitable" | {| class="wikitable" | ||
| Line 24: | Line 22: | ||
| | ] || - || - || + || - || + || + | | ] || - || - || + || - || + || + | ||
| |} | |} | ||
| ⚫ | ==References== | ||
| ⚫ | {{reflist}} | ||
| {{Antidepressants}} | {{Antidepressants}} | ||
Revision as of 12:22, 28 April 2009
There are also several chemically unrelated tetracyclic antibiotics based on Tetracycline.
A tetracyclic antidepressant is an antidepressant drug from the tetracyclic drug group. The name tetracyclic is derived from the drug's molecular structure which consists of four ring-like structures in a T-shape (compare tricyclic antidepressant).
Maprotiline (trade named Ludiomil), and mirtazapine (trade named Remeron in the USA, Remergil, Remeron and Zispin in Europe, and Avanza in Australia) are the only two drugs from this group widely used for the treatment of clinical depression. Mianserin was previously available internationally, however in it has been phased out in favor of mirtazapine in most markets.
Research on other tetracyclic antidepressant compounds (for example setiptiline) have been reported in the scientific literature. These other tetracyclic antidepressants are not available for clinical use.
List of tetracyclic antidepressants
According to MeSH the tetracyclic antidepressants have the following effects:
| SRI | NRI | α1/α2 Antagonist | D2 Antagonist | 5-HT2 Antagonist | H1 Antagonist | |
| Amoxapine | + | + | - | + | + | + |
| Maprotiline | + | - | + | + | + | + |
| Mianserin | - | - | + | - | + | + |
| Mirtazapine | - | - | + | - | + | + |